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Abstract
Background: Diabetes mellitus type II afflicts at least 2 million people in Iran. Neuropathy is one
of the most common complications of diabetes and lowers the patient's quality of life. Since
neuropathy often leads to ulceration and amputation, we have tried to elucidate the factors that
can affect its progression.
Methods: In this case-control study, 110 diabetic patients were selected from the Shariati Hospital
diabetes clinic. Michigan Neuropathic Diabetic Scoring (MNDS) was used to differentiate cases
from controls. The diagnosis of neuropathy was confirmed by nerve conduction studies (nerve
conduction velocity and electromyography). The multiple factors compared between the two
groups included consumption of angiotensin converting enzyme inhibitors (ACEI), blood pressure,
serum lipid level, sex, smoking, method of diabetes control and its quality.
Results: Statistically significant relationships were found between neuropathy and age, gender,
quality of diabetes control and duration of disease (P values in the order: 0.04, 0.04, < 0.001 and
0.005). No correlation was found with any atherosclerosis risk factor (high BP, hyperlipidemia,
cigarette smoking).
Conclusion: In this study, hyperglycemia was the only modifiable risk factor for diabetic
neuropathy. Glycemic control reduces the incidence of neuropathy, slows its progression and
improves the diabetic patient's quality of life. More attention must be paid to elderly male diabetic
patients with poor diabetes control with regard to regular foot examinations and more practical
education.
Background
Diabetes mellitus (DM) is one of the most widespread
chronic diseases in the world. Nearly 7.5% of Iranian peo-
ple are affected by DM type II [1]. DM has two types of
complications: microvascular and macrovascular. One of
the most frequently-occurring microvascular complica-
tions is diabetic neuropathy (DN), of which the most
common type is distal symmetrical neuropathy or
polyneuropathy. This results in significant disability and
morbidity [2,3]. Complications of DN include severe
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tion and amputation.
Incidences of polyneuropathy have been reported in 10–
50% of patients with diabetes [3]. At the time of diagno-
sis, neuropathy is present in 10% of diabetic patients and
overall in 50% of patients with a 25-year history of the dis-
ease [4,5]. Life-time risk of foot amputation is 15% in
patients with diabetic polyneuropathy [5]. Polyneuropa-
thy is the first step in the generation of diabetic foot ulcer.
It produces an anesthetic foot defective in proprioception
and therefore exposed to inappropriate loading. Foot
ulcers develop in risk areas that are exact pressure points
[6].
Different hypotheses have been proposed to explain the
various modes of progression of DN. It has been suggested
that consumption of oral hypoglycemic agents such as
glyburide [7] and angiotensin converting enzyme inhibi-
tors (ACEI) inhibit the progression of neuropathy irre-
spective of blood glucose level [8-10]. Atherosclerosis risk
factors are thought to promote DN [6]. The induction of
mononeuropathy is closely associated with high blood
pressure (BP), hyperlipidemia and cigarette smoking [6].
Since neuropathy can lead to ulceration and amputation,
we have tried to assess the relationships between these risk
factors and sensory/motor polyneuropathy. Early diagno-
sis and treatment of DN is important for preventing sec-
ondary complications and improving quality of life.
Methods
One hundred and ten diabetic patients participated in this
case-control study (55 patients in each group). Controls
and cases were chosen from the Shariati Hospital diabetes
outpatient clinic by simple randomized sampling. A con-
trol subject was a diabetic patient with no evidence of DN,
and a case was a diabetic patient with neuropathy. The
patients' ages ranged between 20 and 80 years. Exclusion
criteria were creatinine >2 mg/dl, specific neurological
disease (M.S, stroke, etc.), other causes of neuropathy (B12
deficiency, alcoholism, etc.), loss of dorsalis pedis pulses
and less than 5 years duration of disease. Informed con-
sent was completed by all participants before they were
enrolled in the study. The study design was approved by
the research ethics committee of the Endocrinology and
Metabolism Research Center of Tehran University of Med-
ical Sciences.
In order to differentiate between cases and controls, Mich-
igan Neuropathic Diabetic Scoring (MNDS) was used
[11]. This system gives a score in the range 0–8, based on
evaluation of 4 different factors in the each leg. These fac-
tors are: appearance of foot (dry skin, callus, deformities,
fissure, and infection), presence of ulcer, Achilles tendon
reflex and vibration perception in the great toe (measured










More than 6 months of withdraw 14.5
less than 10 cigarette/day 7.3
Hypercholesterolemia 42.7
Table 1: Comparison of variables between patients with and without diabetes neuropathy
Variables Patients with neuropathy Patients without neuropathy p-value
Age (year) 58.4 ± 10.5 55 ± 10.7 0.04
Sex 61.8% F, 38.2% M 81.8% F, 18.2% M 0.02
FBS (mg/ml) 143.6 ± 60.2 130.8 ± 63.5 0.13
BS2hpp (mg/ml) 252 ± 82 234 ± 86 0.09
HbA1C(%) 8.2 ± 2.5 7.9 ± 2.7 0.42
Total cholesterol (mg/dl) 214.9 ± 26.4 193.3 ± 29.3 0.001
Duration of disease (year) 14.2 ± 7.4 11.6 ± 9.4 0.03
MNDs Score 5.5 ± 1.4 1.1 ± 5.9 0.0001Page 2 of 5
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given a score of 0.5 or 1 on the basis of the relevant signs.
This scoring system has sensitivity and specificity of nearly
95% [12]. A neuropathic foot usually scores 3 or higher, a
normal foot 2.5 or lower. Cases with a diagnosis of neu-
ropathy according to the Michigan scoring system were
confirmed by nerve conduction studies (EMG-NCV). For
this purpose, nerve conduction velocity, amplitude, dura-
tion and latency were assessed in 5 sensory/motor nerves
(Median, Ulnar, Tibial, Proneal and Sural) on the non-
dominant side of the body. At least one abnormal test in
more than one of these nerves was considered indicative
of neuropathy [11].
Detailed information on each patient's age, sex, type and
duration of diabetes mellitus, mode of treatment (insulin,
oral hypoglycemic agents or both), degree of blood glu-
cose control (bad, fair, good), presence of hypertension,
hyperlipidemia (serum total cholesterol level), ACEI con-
sumption and smoking was recorded and compared
between cases and controls.
The quality of diabetes control was classified according to
the average glycosylated hemoglobin (HbA1C) over the
previous year. Average HbA1C ≤7.5 was considered good
quality control; average 7.6< HbA1C ≤9 was considered
fair control, and average HbA1C ≥9.1 poor control. All nec-
essary data were retrieved from the patient records in the
diabetes outpatient clinic of Shariati Hospital. Patients
with BP≥140/90 were considered hypertensive. Patients
with total cholesterol ≥250 were considered hyperlipi-
demic. HbA1C was measured by HPLC. The total choles-
terol level was measured by calorimetry (Pars Azmoon
kit), and fasting blood sugar (FBS) by the glucose oxidase
method (Pars Azmoon kit).
SPSS 10 software was used for data entry and analysis.
Since multiple factors were analyzed, multivariate analy-
sis was used. Logistic regression was the appropriate mode
for analyzing the multiple risk factors in cases and con-
trols
Results
Of the 110 patients, 78% (79) were female and 22% (31)
were male. The mean age was 55.1 ± 13.2 (20–80 years).
All but one of the patients had type II DM. Mean fasting
blood glucose and average duration of disease in the study
population were 140.5 ± 8 mg/dl and 12.9 ± 7 years,
respectively. Table 1 shows age, duration of disease, mean
FBS, mean 2 hour post-parendial blood glucose
(BS2hpp), HbA1C and total cholesterol in cases and con-
trols. Table 2 shows the frequency of potential risk factors
for polyneuropathy in the study population. No signifi-
cant relationships were found between distal symmetric
sensory/motor polyneuropathy and cigarette smoking,
ACEI consumption, BP or cholesterol level.
Multivariate analysis revealed statistically significant rela-
tionships between DN and age, gender, degree of diabetes
control and duration of disease (P values: 0.04, 0.04, <
0.001 and 0.005, respectively). Neuropathy was more fre-
quent in men than women (odds ratio male/female 2.9,
figure 1). The multivariate analysis results are shown in
Table 3.
Poor diabetes control increases the likelihood of neurop-
athy 0.3 times (odds ratio good control/bad control 0.3
and fair/bad 0.2). Figure 2 shows the relationship
between quality of diabetes control (good, fair and bad)
and MNDS score. Each additional year of disease increases
the likelihood of neuropathy 1.1-fold.
Table 3: The association of sex, duration of disease and quality of 
diabetes control with diabetic neuropathy (result of multivariate 
analysis, logistic regression)




Duration of disease 5.1 0.005 1.1
Quality of diabetes control 
(fair/bad)
-2.2 <0.001 0.2
Quality of diabetes control 
(good/bad)
-1.2 0.04 0.3
Constant -0.54 0.29 1.7
Box plot demonstrating relationship between MNDS score and sex (0 = male, 1 = fem le)Figure 1
Box plot demonstrating relationship between MNDS score 
and sex (0 = male, 1 = female). The dark line in the plot is 
equivalent to mean MNDS score. Average score is higher in 
males.Page 3 of 5
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Diabetic polyneuropathy is a common complication of
DM with high morbidity and impairment of quality of
life. Tesfye et al. [13] studied 3,250 diabetic patients and
reported an overall prevalence of peripheral neuropathy
in 28% of them. The condition was significantly associ-
ated with age, duration of disease, height, diastolic blood
pressure, smoking status, low HDL cholesterol level, high
triglyceride level and HbA1C.
The Ashok study [14] showed significant relationships
only with age and duration of disease. No other associa-
tion was detected. Other studies have shown associations
of neuropathy with age [14-19], duration of disease [14-
20], metabolic control [15,18-21], height [15,22,23], cig-
arette smoking [15,19,24], retinopathy [15,21] and
reduced HDL level [15]. The results of the present study
confirm previous reports regarding the association of neu-
ropathy with male gender, age, glycemic control (HbA1C)
and duration of disease. Our data are also concordant
with the DCCT (Diabetes Control and Complications
Trial) [25] and UKPDS (United Kingdom Prospective Dia-
betes Study) results [26], which used EMG-NCV to iden-
tify neuropathic patients. Our finding that male gender is
associated with neuropathy is consistent with the DCCT
report [25]. Therefore, it can be concluded that MNDS cri-
teria can be used with high confidence as an outpatient
screening method. In our study, no statistically significant
relationship was found between peripheral neuropathy
and ACEI or consumption of oral hypoglycemic agents.
Polyneuropathy was not significantly related to BP, smok-
ing or hyperlipidemia. Most of our patients were non-
smokers, so it was impossible to examine the possible
association between smoking and neuropathy critically.
Further studies using a randomized clinical trial are
needed to evaluate the effects of ACEI and oral hypoglyc-
emic agents on neuropathy.
Conclusion
Since hyperglycemia is a modifiable risk factor for diabetic
neuropathy, intensive glycemic control is the most effec-
tive established therapy for reducing the incidence or
slowing the progression of neuropathy and improving
quality of life in diabetic patients. According to the results
of the present study, better care should be given to elderly
male diabetic patients with poor diabetic control in terms
of regular foot examinations and more practical educa-
tion.
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